EUVIMEDEUVIMED entdecken
Crossref

Inhibition of GRK2 ameliorates the pristane-induced mouse SLE model by suppressing plasma cells differentiation

Dafei Han, Chunru Jiang, Huihui Xu, Rui Chu, Renhao Zhang, Ruhong Fang, Hui Ge, Meiyue Lu, Mingzhu Wang, Yu Tai, Shangxue Yan, Wei Wei und 1 weitere

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Dafei Han und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui C…. Hauptthemen laut MEDLINE: Disease Models, Animal, G-Protein-Coupled Receptor Kinase 2, Lupus Erythematosus, Systemic, Plasma Cells. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by diverse clinical manifestations and organ damage. Despite its elusive etiology, dysregulated subsets and functions of B cells are pivotal in SLE pathogenesis. Peoniflorin-6'-O-benzene sulfonate (CP-25), an esterification modification of Paeoniflorin, exhibits potent anti-inflammatory and immunomodulatory properties in autoimmune diseases (AID). However, the involvement of CP-25 and its target, GRK2, in SLE development has not been explored. In this study, we demonstrate that both genetic deficiency and pharmacological inhibition of GRK2 attenuate autoantibodies production, reduce systemic inflammation, and mitigate histopathological alterations in the spleen and kidney in the pristane-induced mouse SLE model. Importantly, our findings highlight that both genetic deficiency and pharmacological inhibition of GRK2 suppress plasma cells generation and restore dysregulated B-cell subsets by modulating two crucial transcription factors, Blimp1 and IRF4. Collectively, targeting GRK2 with CP-25 emerges as a promising therapeutic approach for SLE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease Models, AnimalG-Protein-Coupled Receptor Kinase 2Lupus Erythematosus, SystemicPlasma CellsAnimalsFemaleMiceAnti-Inflammatory AgentsAutoantibodiesCell DifferentiationGlucosidesKidneyMice, Inbred C57BLMice, KnockoutMonoterpenesPositive Regulatory Domain I-Binding Factor 1SpleenTerpenes

Stichwörter der Autor:innen

B lymphocytesBlimp1CP-25GRK2IRF4SLE

Substanzen

Anti-Inflammatory AgentsAutoantibodiesG-Protein-Coupled Receptor Kinase 2GlucosidesGRK2 protein, mouseMonoterpenespaeoniflorin-6'-O-benzenesulfonatePositive Regulatory Domain I-Binding Factor 1Prdm1 protein, mousepristane

Autor:innen und Institutionen

  • Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicin…

Zitieren

APA

Han, D., Jiang, C., Xu, H., Chu, R., Zhang, R., Fang, R., Ge, H., Lu, M., Wang, M., Tai, Y., Yan, S., Wei, W., & Wang, Q. (2024). Inhibition of GRK2 ameliorates the pristane-induced mouse SLE model by suppressing plasma cells differentiation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112557

Vancouver

Han D, Jiang C, Xu H, Chu R, Zhang R, Fang R, et al. Inhibition of GRK2 ameliorates the pristane-induced mouse SLE model by suppressing plasma cells differentiation. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112557

BibTeX
@article{Han2024,
  author = {Han, Dafei and Jiang, Chunru and Xu, Huihui and Chu, Rui and Zhang, Renhao and Fang, Ruhong and Ge, Hui and Lu, Meiyue and Wang, Mingzhu and Tai, Yu and Yan, Shangxue and Wei, Wei and Wang, Qingtong},
  title = {Inhibition of GRK2 ameliorates the pristane-induced mouse SLE model by suppressing plasma cells differentiation},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112557}
}
Kostenlos starten →